LOGIN  |  REGISTER
Amneal Pharmaceuticals

iRhythm Technologies Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 8, 2024 to Discuss Your Rights - IRTC

February 15, 2024 | Last Trade: US$82.32 8.33 11.26

NEW YORK, Feb. 15, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of iRhythm Technologies, Inc..

Shareholders who purchased shares of IRTC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE

CLASS PERIOD

January 11, 2022 to May 30, 2023

ALLEGATIONS

According to the lawsuit, defendants falsely represented to investors that one of iRhythm's main products, the Zio AT monitor, was a real-time heart monitor intended for high-risk patients. Specifically, defendants repeatedly touted the potential growth for the Zio AT as an innovative product that had only just begun to penetrate the market for real-time monitoring, which investors looked upon favorably given the premium selling price associated with devices approved for high-risk patients. As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the class period.

DEADLINE: April 8, 2024

Shareholders should not delay in registering for this class action. Register your information here.

NEXT STEPS FOR SHAREHOLDERS

Once you register as a shareholder who purchased shares of IRTC during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 8, 2024. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM?

The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: (646) 453-8903

Terns Pharmaceuticals

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB